This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.

While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses, struggling Allakos is welcoming a $0.33 per share buyout offer wi ...

After enacting a “poison pill” defense to protect itself from unwanted potential buyers, Bausch Health has spotted a major ...

Bausch Health has launched a shareholder rights plan—also known as a poison pill defense—designed to prevent any one entity ...

Shares of Keros Therapeutics (NASDAQ:KROS) added ~22% in the premarket on Thursday after the biotech commenced a review process to evaluate different strategic options, including a potential sale of ...

Keros Therapeutics has adopted a poison pill defense to fend off hostile takeovers, after some investors indicated a desire to influence the control of the drug developer. The poison pill, known as a ...

Keros Therapeutics said on Thursday its board had authorized a stockholder rights plan, also known as a "poison pill", in response to rapid accumulations of the company's stock by some investors.

Sunnova Energy International's poison pill comes after the company said its status as a going concern was at risk, announced job cuts and named a new CEO. Houston-based solar energy company ...

St. Louis Post-Dispatch parent Lee Enterprises on Wednesday said its board has extended a "poison pill" shareholder rights plan amid takeover interest from the Hoffmann Family of Cos. St. Louis ...